FDA Investigator Jacqueline A O'shaughnessy, PhD

Jacqueline A O'shaughnessy, PhD has inspections in 2 countries as of 14 Jul 2023. Jacqueline A O'shaughnessy, PhD has collaborated with a combinined 2969 experts on various inspections, contributing to compliance and improvement across diverse sectors.

Investigator Details

Number of Inspected Sites:
74
Last Inspection Date:
14 Jul 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
100000746
Country:
United States of America, Canada
Co-Investigator(s):
Albert F Peacock, PhD, Allen F Hall, Ana P Barido, Andrea A Branche, Andrew R Wasko, Annemarie Bodnar, Anthony E Keller, RPh, Antoinette L Ravelli, Arindam Dasgupta, PhD, Barbar J Breithaupt, Barbara J Holladay, Barbara Janine Breithaupt, Barbara M Frazier, Brandon L Mariner, Brooke K Higgins, Brunilda Torres, Candice C Mandera, Candice C Mandero, Candice J Cortes, Carl A Anderson, Carl J Montgomery, Carla C Tuite, Carol Mrivera Lopez, PhD, Carol Rivera Lopez, PhD, Carr Sharpe, Catherine Whiteside, PhD, Charles Kerns, Charles M Kerns, BLT DO, Charles R Bonapace, PhD, Chris J Drabick, Christine M Smith, Christine M Whitby, CSO, Connie P Rezendes, Courtney N Long, Ct Viswanathan, PhD, Cynthia A Harris, MD, RN, Da Lin Yao, MD, PhD, Dana M Klimavicz, David K Glasgow, Dhaval H Patel, Dianne H Milazzo, Donald B Mckechnie, Doreen P Gubbay, Dr. Abhijit Raha, PhD, Dr. Gopa Biswas, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Dylan D Yao, MD, PhD, Edward Oshaughnessy, Elise A Murphy, Emest F Bizjak, Erin L Mcfiren, Erin M Mcdowell, George C Amedro, Gianine E Tompkins, Gifford Whitehurst, Jr, Gopa Bisivas, Grace P Santos, Hector J Colon Torres, Heika R Bounds, Heika R Tait, Herrmann, Hitesh R Patel, Hugh M Mcclure, II, Huixia Zhang, Iris C Macinnes, Jackie O'shaughnessy, Jacqueline A O'shanghnessy, PhD, Jacqueline N O'shaughnessy, Jane M Kreis, Jaqueline A O'shaughnessy, Jason M Sluzynski, Jeanne D Shaffer, Jennifer Alongie Vollom, Jodi M Gatica, John A Kadavil, PhD, John J Walsh, John J Welsh, PhD, John Kadavil, PhD, Judith A Jones, Judith A Paterson, Julian C Hanson, Kalavati Suvarna, PhD, Karen L Kosar, Karen M Kondas, Kathryn A Krentz, Kelly Doremus, Kelly I Anderson, Kenneth Nieves, Larry K Austin, Lawrence R Johnson, Linda S Leja, Linda Thai, Lisa B Orr, Lisa P Oakes, Lori J Silverstein, LT Melanie M Mayor, USPHS, Lynette P Salisbury, Marcelo O Mangalindan, Jr, Margaret M Annes, Maria Pkelly Doggett, MBA, Martin K Yan, PhD, Martin K Yau, PhD, Mathew R Manen, Matthew R Mcnew, Melissa B Libby, Melissa J Garcia, Meyer, Michael F Skelly, PhD, Michael J Nerz, Michael Rosner, Mike M Rashti, Nathaniel R Esaw, Nilufer M Tampal, PhD, Patrick D Stone, MS, Paula J Bretz, Raymond L Cheung, Robert Barron, Robert C Steyert, Sam H Haidar, PhD, Samuel H Chan, PharmD, Sarah Forney, Scott B Laufenberg, Sean Y Kassim, PhD, Sherry I Seerist, Sherry L Secrist, BLT DO, Spiram Subramaniam, PhD, Srinivas R Chennamaneni, PhD, Sripal R Mada, PhD, State Agency, Stephanie I Shapley, Stephanie L Shapley, Stephanie Mangigian, MS/OSH, RN, Stephanie T Durso, Steven J Thurber, Stuart W Russell, Sunitha K Rajaram, PhD, Susan F Laska, MS, Tamal K Chakraborti, PhD, Tamika E Allen, RN, Tanika E Allen, RN, Tara K Carmody, Tracy L Taras, Veronica Bush, Veronica L Bush, Vickie J Kanion, Vlada Matusovsky, Wayne J Meyer, William H Linkroum, William J Muszynski, William L Bargo, Xikui Chen (nmi), PhD, Yih Chain Huang, PhD

Jacqueline A O'shaughnessy, PhD's Documents

Publish Date Document Type Title
July, 2000 FDA 483 Response Covance Laboratories, Inc. - Form 483R, 2000-08-25
November, 2000 FDA 483 Response Covance Laboratories, Inc. - Form 483R, 2000-11-28
July, 2004 EIR PPD Development, L.P. - EIR, 2004-07-21
June, 2010 FDA 483 Pfizer Inc. - Form 483, 2010-06-11
November, 2000 FDA 483 Covance Laboratories, Inc. - Form 483, 2000-11-02
July, 2004 FDA 483 Response PPD Development, L.P. - Form 483R, 2004-08-16
March, 2001 FDA 483 Altasciences Company Inc. - Form 483, 2001-03-09
October, 2004 EIR MDS Pharma Services - EIR, 2007-06-15
June, 2009 EIR Merck & Company, Inc. - EIR, 2009-06-05
May, 2006 FDA 483 Response PPD Development, L.P. - Form 483R, 2006-06-13
April, 2000 FDA 483 Bioanalytical Systems Inc - Form 483, 2000-04-28
May, 2006 EIR PPD Development, L.P. - EIR, 2006-05-17
December, 2005 FDA 483 PPD Development, L.P. - Form 483, 2005-12-15
October, 2004 EIR PPD Development, L.P. - EIR, 2004-10-14
October, 2000 FDA 483 Biovail Contract Research - Form 483, 2000-10-27
November, 2009 EIR Altasciences Preclinical Seattle, LLC - EIR, 2009-11-20
June, 2003 FDA 483 Biovail Contract Research - Form 483, 2003-06-13
August, 2000 EIR Frederick G. Hayden, M.D. - EIR, 2000-08-11
March, 2001 FDA 483 Response Algorithme Pharma Inc. - Form 483R, 2001-03-23
May, 2010 FDA 483 Cetero Research - Form 483, 2010-05-07
March, 2008 FDA 483 PPD Development, L.P. - Form 483, 2008-03-11
August, 2000 FDA 483 Response Frederick G. Hayden, M.D. - Form 483R, 2000-08-21
March, 2001 EIR Algorithme Pharma Inc. - EIR, 2001-04-02
October, 2010 FDA 483 Human Genome Sciences Inc - Form 483, 2010-09-24
November, 2009 FDA 483 Altasciences Preclinical Seattle, LLC - Form 483, 2009-11-20
July, 2004 FDA 483 PPD Development, L.P. - Form 483, 2004-07-21
October, 2000 EIR Biovail Contract Research - EIR, 2000-10-27
August, 2002 EIR American Histolabs Inc - EIR, 2002-08-22
July, 2000 EIR Covance Laboratories, Inc. - EIR, 2000-07-27
December, 2000 EIR Bioanalytical Systems Inc - EIR, 2000-12-19
April, 2000 EIR Bioanalytical Systems Inc - EIR, 2000-07-24
December, 2005 FDA 483 Response PPD Development, L.P. - Form 483R, 2005-12-22
August, 2000 FDA 483 University of Virginia Health Sciences Center - Form 483, 2000-08-11
October, 2000 FDA 483 Response Biovail Contract Research - Form 483R, 2000-11-09
December, 2005 EIR PPD Development, L.P. - EIR, 2005-12-15
October, 2004 FDA 483 MDS Pharma Services - Form 483, 2004-09-21
January, 2001 EIR Covance Laboratories, Inc. - EIR, 2001-01-11
July, 2000 FDA 483 Covance Laboratories, Inc. - Form 483, 2000-07-27

Experience Redica System's NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more